Who manufactures Emgality (Galcanezumab)?

Galcanezumab-gnlm bulk supplier for pharma manufacturers

Galcanezumab-Gnlm 120 mg/mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 120 mg/mL

Reference Brands: Emgality (USA/EU)

Category: Neurology

Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a molecule involved in migraine attacks. It is used for the prevention of migraine in adults and for the treatment of cluster headaches. Regular monthly injections help reduce migraine frequency and severity.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Galcanezumab-Gnlm? List it or send an offer →

Product Description:

Galcanezumab is a humanised monoclonal antibody that binds the CGRP ligand, preventing it from activating its receptor. It is indicated for preventive treatment of migraine in adults and, in the US, for treatment of episodic cluster headache — the only CGRP antibody with that indication, which in clinical trials reduced weekly attack frequency during a cluster period.

For migraine it starts with a 240 mg loading dose, given as two injections, followed by 120 mg monthly. The loading dose brings concentrations to steady state quickly, and trial benefit over placebo was evident in the first month. For episodic cluster headache the dose is 300 mg monthly during the cluster period. Injection site reactions are the most common adverse effect, and hypersensitivity reactions — including some occurring days after injection — are recognised. Hypertension and constipation have been reported post-marketing with CGRP-pathway antibodies.

Sourcing notes. Originator biologic, on patent, without a biosimilar. Supplied as prefilled pens or syringes needing refrigeration. The cluster headache indication is not registered in every market that registers the migraine indication, so a buyer's intended use should be checked against local labelling. Reimbursement typically requires failure of prior preventive treatments. Treat enquiries as authorised-distributor supply.

How Galcanezumab-Gnlm is supplied today, and licensing ahead of patent expiry

Galcanezumab-Gnlm is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Galcanezumab-Gnlm, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Galcanezumab-Gnlm supply →

Back to Listing

Frequently Asked Questions

Emgality (Galcanezumab) is developed and sold by Eli Lilly. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.